Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsCURLF -2.70%72 Days Sales Outstanding is 20.34 as of Mar. 2026, which is 23% above its 10-year median of 16.48. GuruFocus rates CURLF with a GF Score™ of 72/100 and a GF Value™ of $8.04 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 949 Drug Manufacturers companies, Curaleaf Holdings ranks better than 94.73% on this metric.
The historical rank and industry rank for Curaleaf Holdings's Days Sales Outstanding or its related term are showing as below:
CURLF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.23 Med: 16.48 Max: 25.07
Current: 19.57
During the past 12 years, Curaleaf Holdings's highest Days Sales Outstanding was 25.07. The lowest was 14.23. And the median was 16.48.
CURLF's Days Sales Outstanding is ranked better than 94.73% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs CURLF: 19.57
Curaleaf Holdings's Days Sales Outstanding
increased
from Mar. 2025 (18.76) to Mar. 2026 (20.34).
Curaleaf Holdings (OTCPK:CURLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Curaleaf Holdings Days Sales Outstanding Related Terms
Curaleaf Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Days Sales Outstanding falls into.
Curaleaf Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a Days Sales Outstanding of 20.34 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Curaleaf Holdings and its competitors. This is 23% above median its historical median of 16.48. Over the past decade, Curaleaf Holdings' Days Sales Outstanding has ranged from 14.23 to 25.07. According to the industry distribution chart, Curaleaf Holdings ranks #50 out of 949 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Curaleaf Holdings' Days Sales Outstanding too high?
Curaleaf Holdings' current Days Sales Outstanding of 20.34 is 23% above median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 14.23 to a high of 25.07. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Curaleaf Holdings' value of 20.34 is 71.8% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #50 out of 949 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #50 out of 949 companies for Days Sales Outstanding. This places Curaleaf Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 72.00. Curaleaf Holdings' value of 20.34 is 71.8% below this benchmark. Historically, Curaleaf Holdings' own Days Sales Outstanding has ranged from 14.23 to 25.07 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 72.00, Curaleaf Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Days Sales Outstanding of 20.34 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Days Sales Outstanding is 20.34, which is 23% above median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.04, compared to a current price of $9.00 — trading 11.9% above its estimated fair value. The current Days Sales Outstanding is 20.34, which is 23% above median its 10-year median of 16.48 and 71.8% below the Drug Manufacturers industry median of 72.00. Curaleaf Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Days Sales Outstanding is 20.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.00 is trading 11.9% above its estimated GF Value™ of $8.04.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Days Sales Outstanding: 20.34 (23% above median its 10-year median of 16.48)
GF Value™: $8.04 vs. price of $9.00 (11.9% above fair value)
Industry Position: 71.8% below the Drug Manufacturers median (#50 of 949)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
72GF Score
Get the complete analysis for CURLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
